Physician profile
Neeta R Motiwala
NPI 1538153531
$2,901.72
in general payments reported to CMS, 2019-2025
34 companies · $1,308 in 2025
The $1,308 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $636 · 2020: $25.82 · 2022: $86.59 · 2023: $124 · 2024: $722 · 2025: $1,308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,153.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $544.11 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Corcept Therapeutics | $291.43 | 2024-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $275.85 | 2019-2025 | Airsupra, Breztri |
| Abbvie INC. | $222.67 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.85 | 2025 | Jardiance |
| Amgen INC. | $150.34 | 2019-2020 | |
| Cvrx, INC. | $149.35 | 2024 | Barostim Neo System |
| Astellas Pharma US INC | $142.22 | 2024-2025 | Veozah |
| Ibsa Pharma INC. | $125.00 | 2024 | Tirosint |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.30 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $93.26 | 2019-2025 | Tremfya |
| Glaxosmithkline, LLC. | $73.33 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Asensus Surgical, INC. | $55.87 | 2023 | Senhance |
| Allergan, INC. | $52.13 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.06 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $36.61 | 2023 | Minimed 780g |
| Shire North American Group INC | $36.03 | 2019 | |
| Merck Sharp & Dohme LLC | $27.79 | 2019 | |
| Exact Sciences Corporation | $25.19 | 2025 | Cologuard Collection Kit |
| Ucb, INC. | $23.65 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $20.55 | 2025 | |
| Kyowa Kirin, INC. | $19.98 | 2025 | |
| Cleerly, INC. | $19.50 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Boston Scientific Corporation | $19.10 | 2019 | |
| Phathom Pharmaceuticals, INC. | $18.60 | 2025 | Voquezna |
| Echosens North America, INC. | $15.30 | 2024 | Fibroscan |
| Biohaven Pharmaceutical Holding Company LTD. | $15.00 | 2022 | |
| Octapharma USA, INC. | $15.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.94 | 2019 | |
| Pfizer INC. | $13.22 | 2019 | |
| Ironwood Pharmaceuticals, INC | $12.38 | 2019 | |
| Adlon Therapeutics L.P. | $12.21 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.53 | 2019 | |
| Genentech USA, INC. | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neeta Motiwala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.